DXRX
NEUTRALDiaceutics Announces PDMR Shareholding and Share Incentive Plan
The healthcare technology company announces changes to PDMR shareholdings and the implementation of a share incentive plan for employees.
Diaceutics
125.00GBX
2.88%
Market Cap
105.65M
Volume
71.17k
86% of avg
P/E Ratio
0.63
EPS (TTM)
1.99
Beta
0.82
Day Range
123.50p - 127.00p
52 Week Range
96.00p125.00p151.00p
125.00p
Upcoming Events
DXRX
NEUTRALDiaceutics Announces Upcoming Results Presentation
The healthcare technology company announces plans to release its annual results and hold investor presentations.
DXRX
NEUTRALDiaceutics PLC Announces PDMR Shareholding and Share Incentive Plan
The healthcare technology company announces changes to its PDMR shareholdings and share incentive plan.
DXRX
VERY GOODDiaceutics Secures Lucrative PMx Contract Extension with Partner Therapeutics
The diagnostic commercialization company secures a lucrative contract extension with a major pharmaceutical partner, potentially worth up to £18.5 million in recurring service revenues over the next several years.
DXRX
NEUTRALDiaceutics PLC Announces Change in Shareholding
The diagnostic company has announced a change in its shareholder base, with Danske Bank A/S increasing its stake to 3.99% of the voting rights.
DXRX
NEUTRALDiaceutics Announces PDMR Share Purchases Under Incentive Plan
The diagnostic commercialisation company announces PDMR share purchases under its employee incentive plan.
DXRX
NEUTRALDiaceutics PLC Announces Director Share Purchase
The healthcare technology company announces a non-executive director has purchased a small number of shares, a routine regulatory disclosure.
DXRX
NEUTRALDiaceutics PLC Announces Director Share Purchases Under Incentive Plan
The healthcare technology company announces director share purchases under its employee incentive plan, a common regulatory disclosure unlikely to significantly impact the business.
DXRX
GOODDiaceutics Reports Strong Revenue Growth in FY 2024 Trading Update
The healthcare technology company reports strong revenue growth of 39% in FY 2024, with EBITDA expected to exceed analyst estimates. The firm's investments in sales and innovation are delivering results, providing good visibility for continued growth.
DXRX
GOODDiaceutics Expands US Footprint with New Headquarters
Diagnostic solutions provider expands US operations with new headquarters, positioning for growth.